pirfenidone IPF
Selected indexed studies
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (BMC Pulm Med, 2021) [PMID:34895203]
- Interstitial Lung Disease: A Review. (JAMA, 2024) [PMID:38648021]
- Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. (Thorax, 2023) [PMID:36948586]
_Worker-drafted node — pending editorial review._
Connections
pirfenidone IPF is a side effect of
Sources
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (2021) pubmed
- Interstitial Lung Disease: A Review. (2024) pubmed
- Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. (2024) pubmed
- Idiopathic pulmonary fibrosis. (2023) pubmed
- Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. (2024) pubmed
- Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. (2023) pubmed
- Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. (2017) pubmed
- Inflammation and immunity in IPF pathogenesis and treatment. (2019) pubmed
- Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. (2021) pubmed
- Idiopathic pulmonary fibrosis: pathogenesis and management. (2018) pubmed